RBC Capital Reiterates Outperform on Pacira BioSciences, Maintains $68 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza has reiterated an Outperform rating on Pacira BioSciences (NASDAQ:PCRX) and maintained a $68 price target.
October 03, 2023 | 2:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has reiterated an Outperform rating on Pacira BioSciences and maintained a $68 price target.
The reiteration of an Outperform rating by RBC Capital indicates a positive outlook for Pacira BioSciences. The maintained price target of $68 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100